AST2303 / Abbisko, Allist - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Allist Pharmaceuticals, Inc.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Heyu-B(02256): ABK3376 received IND approval from the National Medical Products Administration [Google translation] (Zhitong Finance) - "According to the Zhitong Finance APP, Heyu-B (02256) issued an announcement that its subsidiary Shanghai Heyu Biotechnology Co., Ltd. (Heyu Pharmaceutical) announced that its independently discovered and co-developed new generation EGFR oral small molecule inhibitor ABK3376 with Shanghai Elis Pharmaceuticals Co., Ltd. (Ellis) has been approved by the China National Medical Products Administration for the first human Phase I clinical trial for the treatment of non-small cell lung cancer with EGFR-C797S resistance mutation."

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Heyu-B (02256) Subsidiary reached a license agreement with Alice on ABK3376 [Google translation] (Zhitong Finance) - "Zhitong Finance APP News, Heyu-B...announced that on March 1, 2023, the company's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. Co., Ltd. (ALIS) signed an exclusive license agreement to further research, develop, manufacture, use and sell a new generation of small molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ABK3376 in China....According to the terms of the agreement, Harmony Medicine will receive an upfront payment of up to US$188 million, development and sales milestone payments, and a corresponding percentage of net sales license royalties."

Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor